No connection

Search Results

NSYS

NEUTRAL
$14.48 Live
Nortech Systems Incorporated · NASDAQ
$6.5 52W Range $14.56

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 16, 2026
Market cap
$40.34M
P/E
N/A
ROE
-0.7%
Profit margin
-0.2%
Debt/Equity
0.45
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
80%
NSYS exhibits a severe disconnect between its fundamental health and recent price action. The Piotroski F-Score of 2/9 indicates weak operational efficiency and financial deterioration, yet the stock is trading near its 52-week high with significant 1-year gains (+82.1%). While valuation metrics like Price/Sales (0.34) and Price/Book (1.18) suggest the company is undervalued relative to its assets and revenue, the thin profit margins and sluggish growth (5.9%) provide little fundamental support for the current price surge.

Key Strengths

Very low Price-to-Sales ratio (0.34) suggesting deep value
Strong liquidity with a Current Ratio of 1.88
Manageable leverage with a Debt/Equity ratio of 0.45
Exceptional short-term price momentum (+50.2% in 1 month)
Trading close to book value (P/B 1.18)

Key Risks

Critically low Piotroski F-Score (2/9) signaling poor financial health
Very thin gross margins (15.21%) for the medical device industry
Stagnant revenue growth (5.9%) compared to healthcare sector averages
Negative Return on Equity (-0.73%) indicating failure to generate shareholder value
Extreme micro-cap volatility and lack of institutional analyst coverage
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
-13.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
45
Moderate
Value
85
Future
30
Past
90
Health
20
Dividend
0
AI Verdict
Speculative Momentum
Key drivers: Price momentum, Low valuation multiples, Poor operational health (F-Score)
Confidence
85%
Value
85/100

Valued primarily on assets and sales rather than earnings.

Positives
  • P/S of 0.34 is significantly undervalued
  • P/B of 1.18 is attractive
Watchpoints
  • Lack of earnings makes P/E and Graham Number unavailable
Future
30/100

Growth rates are insufficient to justify a high-growth premium.

Positives
  • Positive revenue growth
Watchpoints
  • Growth rate (5.9%) is anemic for the healthcare sector
  • Negative profit margins
Past
90/100

Price performance has been the primary driver of interest.

Positives
  • Strong 1Y (+82.1%) and 6M (+46.3%) returns
  • Consistent upward trend over 5 years
Watchpoints
  • Technical trend score (10/100) suggests a potential peak or reversal
Health
20/100

Operational health is weak despite adequate short-term liquidity.

Positives
  • Healthy Current and Quick ratios
Watchpoints
  • Piotroski F-Score of 2/9 is a major red flag
  • Negative ROE
Dividend
0/100

Non-dividend paying growth/recovery play.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$14.48

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NSYS and closest competitors.

Updated 2026-04-15
NSY
Nortech Systems Incorporated
Primary
5Y
+117.1%
3Y
+37.4%
1Y
+82.1%
6M
+46.3%
1M
+50.2%
1W
+7.6%
INC
InterCure Ltd.
Peer
5Y
-91.7%
3Y
-67.4%
1Y
-37.5%
6M
-52.3%
1M
-4.7%
1W
+0.4%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
BDM
Baird Medical Investment Holdings Limited
Peer
5Y
-89.3%
3Y
-90.0%
1Y
-87.4%
6M
-49.5%
1M
-26.9%
1W
-10.4%
ATR
Atara Biotherapeutics, Inc.
Peer
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
1.18
P/S Ratio
0.34
EV/Revenue
0.45
EV/EBITDA
21.22
Market Cap
$40.34M

Profitability

Profit margins and return metrics

Profit Margin -0.21%
Operating Margin 2.97%
Gross Margin 15.21%
ROE -0.73%
ROA 1.07%

Growth

Revenue and earnings growth rates

Revenue Growth +5.9%
Earnings Growth N/A
Q/Q Revenue Growth +5.92%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.45
Low debt
Current Ratio
1.88
Good
Quick Ratio
1.13
Good
Cash/Share
$0.59

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
16.7%
Op. Margin
3.0%
Net Margin
3.0%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.08x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
97%

Healthcare Sector Comparison

Comparing NSYS against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-0.73%
This Stock
vs
-100.15%
Sector Avg
-99.3% (Below Avg)
Profit Margin
-0.21%
This Stock
vs
-13.63%
Sector Avg
-98.4% (Weaker)
Debt to Equity
0.45
This Stock
vs
3.22
Sector Avg
-85.9% (Less Debt)
Revenue Growth
5.9%
This Stock
vs
121.05%
Sector Avg
-95.1% (Slower)
Current Ratio
1.88
This Stock
vs
4.55
Sector Avg
-58.7% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning NSYS from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile